Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
David Fivenson(Trinity Health Ann Arbor Hospital), Luca Borradori(University Dermatology), Animesh A. Sinha(University at Buffalo, State University of New York), Daniel Mimouni(Rabin Medical Center), Hiroshi Shimizu(The University of Tokyo), Russell P. Hall(Duke University), David Sirois(Rutgers, The State University of New Jersey), A.R. Ahmed, David A. Rubenstein(University of North Carolina at Chapel Hill), Yasuo Kitajima(Hiroshima University), Victoria P. Werth(Philadelphia VA Medical Center), Michael Hertl(Universitätsklinikum Gießen und Marburg), María A. Barnadas(Universitat Autònoma de Barcelona), Neil J. Korman(University Hospitals of Cleveland), Linda K. Martin(The University of Sydney), Takashi Hashimoto(Osaka Metropolitan University), Luis A. Díaz(Memorial Sloan Kettering Cancer Center), P. Joly(Inserm), Giuseppe Cianchini(Istituto Dermopatico dell'Immacolata), Masayuki Amagai(Keio University), Amit G. Pandya(The University of Texas Southwestern Medical Center), Marcel F. Jonkman(University Medical Center Groningen), Detlef Zillikens(University of Lübeck), Pilar Iranzo, Karen Harman(University Hospitals of Leicester NHS Trust), Jean‐Claude Bystryn, Nico Hunzelmann(University of Cologne), Dédée F. Murrell(Sutherland Hospital), Sarah Dick, Aimee Payne(Columbia University Irving Medical Center)
Cited by 0
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Cancer Genome Landscapes
|Science|2013|8k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k